This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.

PRIMARY OBJECTIVES:

I. Determine the cellular and mechanistic basis of bone marrow (BM) hematopoietic dysfunction in untreated MBL and CLL patients.

II. Determine if MBL and CLL B cell derived cellular products directly alter the differentiation and functional capacities of Hematopoietic Stem and Progenitor Cells (HSPCs).

III. Utilize the Emu-Tcl1 transgenic mouse model to determine how MBL and CLL patient-derived cellular products alter BM hematopoiesis.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and bone marrow aspiration and biopsy and have their medical records reviewed on study.

Inclusion Criteria:

• Subjects in the CLL cohort who are eligible for these studies will have a clinically established diagnosis of CLL as assessed by flow cytometry and will include subjects who

  • Remain untreated
  • Are currently being treated
  • Who have already been treated

• Subjects in the MBL cohort will have a clinically established diagnosis of MBL

• Healthy age-matched control subjects

• Healthy younger control subjects aged > 40 years

Exclusion Criteria:

• Anyone under 40
• Healthy control subjects must not have a diagnosis of CLL or MBL

Patients with MBL, patients with CLL ,and healthy subjects recruited through Mayo Clinic.